Coeptis Therapeutics Dave Mehalick on Making Cell Therapy Universally Accessible [Video]

In a recent interview with InvestorNews, Dave Mehalick, Chairman, President, and CEO of Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), discussed the company’s innovative approaches in cell therapy, highlighting their focus on making such treatments more universally accessible. Mehalick explained, “What we are working on is not failing, it’s working. We’ve been able to create cells, not have to match those cells at all to the individual patient. Put those same cells in any patient and their body is accepting them and they are going to work.” This strategy represents a shift from the traditional and costly autologous cell therapy to a more cost-effective allogeneic approach, potentially lowering the future cost of cell therapies and making them accessible to a broader population.

Furthermore, Coeptis Therapeutics has been actively forming partnerships with top academic institutions such as Duke University and the University of Pittsburgh. Mehalick shared details about their exclusive license agreement with the University of …